Evidence map›Paper›PMID 40248858›Full record

Trial reportMultiple sclerosis (Houndmills, Basingstoke, England)2025

Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study.

Robert J Fox, Stanley Cohan, Yang Mao-Draayer, Bianca Weinstock-Guttman, Linda-Ali Cruz, Sophie Arnould, Gina Mavrikis Cox, Amit Bar-Or

Registry-linked trialAbstract readMulticenter StudyClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Multiple sclerosis (Houndmills, Basingstoke, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03623243 (Exploring the Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03623243 phase3completednot on this map

Exploring the Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Patients With Advancing Forms of Relapsing Multiple Sclerosis: A 6-month Open Label, Multi- Center Phase IIIb Study

TypeinterventionalSponsorNovartis PharmaceuticalsRan2019 to 2022Enrolled185ConditionsMultiple Sclerosis, Relapsing Multiple Sclerosis, Advancing Multiple SclerosisArmsSiponimod
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Robert J FoxMellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-4263-3717
Stanley CohanProvidence Multiple Sclerosis Center; Providence St. Vincent Medical Center, Portland, OR, USA.
Yang Mao-DraayerAutoimmunity Center of Excellence, Multiple Sclerosis Center of Excellence, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Bianca Weinstock-GuttmanJacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY, USA.ORCID 0000-0001-6732-151X
Linda-Ali CruzNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Sophie ArnouldNovartis AG, Basel, Switzerland.
Gina Mavrikis CoxNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Amit Bar-OrPerelman School of Medicine, University of Pennsylvania, PA, USA.ORCID 0000-0001-7179-0335

Funding

University of Michigan Clinical Autoimmunity Center of ExcellenceUM1AI144298 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FOX, DAVID ALAN, KHANNA, DINESH · 2019 to 2023
$546k
University of Michigan Autoimmunity Center of Excellence, Clinical Research ProgrUM1AI110557 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FOX, DAVID ALAN · 2014 to 2018
$543k
NIAID NIH HHS UM1 AI110557NIAID NIH HHS UM1 AI144298
6 · The paper itself

Abstract

backgroundSiponimod, a sphingosine-1-phosphate (S1P) receptor modulator, reduces relapses and delays disability progression in patients with active progressive multiple sclerosis (MS).

objectiveEXCHANGE assessed the safety/tolerability of siponimod in patients with advancing relapsing MS (RMS) converting from other disease-modifying therapies (DMTs).

methodsThis 6-month, open-label, multicenter, single-arm, phase 3b study (NCT03623243) enrolled 185 patients with advancing RMS previously treated with other DMTs for ⩾3 months. Patients were converted to siponimod via a 6-day dose-titration regimen, or converted immediately, depending on prior DMT use.

resultsTreatment-related adverse events (AEs) were reported by 31.9% (59/185) of patients, with headache (8.1%,

conclusionConversion to siponimod from other DMTs was found to be generally well tolerated. Patients switching from other S1P-receptor modulators may be able to immediately transition to the siponimod maintenance dose without effects on HR. CLINICAL

trial registrationClinicalTrials.gov: NCT03623243 (https://clinicaltrials.gov/study/NCT03623243).

Indexed as

AzetidinesBenzyl CompoundsDrug SubstitutionMultiple Sclerosis, Relapsing-RemittingSphingosine 1 Phosphate Receptor ModulatorsAdultDisease ProgressionFemaleHumansMaleMiddle AgedAzetidinesBenzyl CompoundssiponimodSphingosine 1 Phosphate Receptor ModulatorsBradycardiamultiple sclerosisS1P modulatorsafetysecondary progressive multiple sclerosissiponimodtreatment satisfaction

Identifiers

PMID40248858
PMCPMC12280243

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.